Millennium, The Takeda Oncology Company today announced the publication of an article in the journal Blood describing the novel mechanism of action of MLN4924 through targeted pathway modulation in diffuse large B-cell lymphoma (DLBCL). Continue Reading
Aethlon Medical, Inc., the pioneer in developing therapeutic filtration devices to address infectious disease and cancer, announced today that the Medanta Independent Ethics Committee (MIEC) at Medanta, The Medicity Institute (Medicity) has approved a treatment program entitled “Use of the Aethlon Hemopurifier in Treating Chronic HCV Infection in Combination with Standard of Care (SOC) Drug Therapy.” Continue Reading
Plexxikon today announced publication of data from the Phase 1 clinical trial of PLX4032 (RG7204), confirming that treatment of metastatic melanoma patients with the BRAF V600E mutation resulted in significant tumor shrinkage in the majority of patients. Specifically, in the melanoma extension cohort of the study, nearly all patients showed some response; 81 percent of patients had tumor shrinkage of at least 30 percent. Continue Reading
According to a new study, berries like strawberries, blueberries and acai berries help to recycle toxic proteins that are linked to age-related memory loss and other mental decline. Continue Reading
Hologic, Inc. (Hologic or the Company), a leading developer, manufacturer and supplier of premium diagnostics products, medical imaging systems and surgical products dedicated to serving the healthcare needs of women, today announced that on July 1, 2010, the Norwegian cervical screening program began reimbursing for liquid-based cytology (LBC). Continue Reading
According to an Australian Melanoma Family study, use of sunbeds to get a tan can increase the risk of developing melanoma by 41 per cent. The study looked into the effects of sunbeds on 18-39-year-olds and found that 23 per cent of participants who had melanoma reported using these machines. Continue Reading
Sanofi-aventis U.S. announced today that the U.S. Food and Drug Administration (FDA) has approved a new one-vial formulation of its chemotherapeutic agent Taxotere® (docetaxel) Injection Concentrate. The 1-vial Taxotere is anticipated to become available to cancer treatment clinics and hospitals nationwide in the fall in both 80 mg and 20 mg dosages. Continue Reading
Accuray Incorporated, a global leader in the field of radiosurgery, announced today it received Shonin approval from the Japanese Ministry of Health, Labor and Welfare to market the CyberKnife G4 Robotic Radiosurgery System to treat tumors non-invasively anywhere in the body, inclusive of head and neck. The System will be marketed in Japan as the “CyberKnife Radiosurgery System.” Continue Reading
In patients with non-small cell lung cancer, five-year disease-free survival is currently the benchmark of cure. However, there are two issues that remain with the follow-up standards: (1) When can cure be declared with confidence and (2) for how long should follow-up examination be continued? Continue Reading
Exact Sciences Corp. today announced that data being presented this afternoon at the annual meeting of the American Association of Clinical Chemistry demonstrates that its methylation specific technology, using a combination of DNA methylation markers, detected 100 percent of colorectal cancers and precancers at a specificity cutoff of 100 percent in a preliminary study with colorectal tissue. Continue Reading
